Thermal Ablation for Papillary Thyroid Microcarcinoma: What Patients Should Know About This Promising Treatment

Table of Contents

• Key Points
• Background: Why Small Thyroid Cancers Matter
• What Is Thermal Ablation?
• Microwave Ablation (MWA)
• Laser Ablation (LA)
• Radiofrequency Ablation (RFA)
• How Thermal Ablation Compares With Surgery
• Complications and Side Effects
• How This Review Was Conducted
• Limitations of the Evidence
• What This Means for Patients
• Frequently Asked Questions
• Source Information

Key Points

• Thermal ablation uses heat to destroy papillary thyroid microcarcinoma (10 mm or smaller) without surgery, guided by ultrasound.
• In reviewed studies, microwave, laser, and radiofrequency ablation shrank tumors by 96% to nearly 100% on average.
• Compared with surgery, thermal ablation had fewer complications, shorter hospital stays, less blood loss, and lower costs.
• Recurrence appeared similar to surgery in the largest comparison: 4.2% with microwave ablation versus 4.2% with surgery.
• Most evidence comes from retrospective studies in Asian populations; large randomized trials are still needed.

Background: Why Small Thyroid Cancers Matter

Thyroid cancer diagnoses have climbed sharply around the world in recent decades. A major driver is not that more people are truly developing aggressive cancer. A major driver is that imaging tests and routine physical exams are finding very small tumors. These very small tumors would never have caused symptoms. Researchers call this overdetection — finding disease that would otherwise have gone unnoticed and possibly never caused harm.

The most common thyroid cancer type is differentiated thyroid carcinoma (DTC), a group of cancers arising from thyroid cells that still resemble normal thyroid tissue. Within that group, papillary thyroid carcinoma (PTC) is the most frequent. When a papillary tumor measures 10 mm or less across (about 0.4 inches), it is called papillary thyroid microcarcinoma (PTMC). PTMC makes up a substantial share of all DTC cases.

Today in China, the standard treatment for PTMC is thyroid lobectomy (removing half the thyroid gland) plus selective central lymph node dissection (SCLND), a procedure that removes nearby lymph nodes in the center of the neck to check for spread. Yet the review authors point out an uncomfortable fact: many of these tiny tumors never grow, or grow extremely slowly, over years of follow-up.

Surgery itself has improved. Techniques have advanced from traditional open thyroidectomy to endoscopic thyroidectomy, in which instruments and a camera are inserted through small incisions. Even so, recent literature still reports surgical complications. This has fueled growing concern about both overdetection and overtreatment of PTMC, and it has driven researchers to look for alternatives.

Two main alternatives have emerged:

• Active surveillance (AS) — carefully monitoring the tumor with repeat ultrasound instead of treating it immediately.
• Thermal ablation (TA) — using heat to destroy the tumor in place.

Some patients find active surveillance difficult to accept. The review notes that a portion of people diagnosed with PTMC experience anxiety and distress about simply "carrying" a tumor. Many of these patients prefer an active intervention over watchful waiting. Thermal ablation has therefore been introduced into clinical practice as an option for patients with low-risk PTMC.

What Is Thermal Ablation?

Thermal ablation refers to techniques that use extreme heat to kill tumor cells. The heat causes coagulation necrosis — a process in which proteins in the cells break down and the tissue dies. The dead tissue is then gradually reabsorbed by the body.

Three main technologies are used for PTMC, and each generates heat differently:

• Microwave ablation (MWA) — high-frequency electromagnetic waves create a broad thermal effect that kills tumor cells quickly through protein denaturation (protein breakdown caused by heat).
• Laser ablation (LA) — a thin fiber connected to a continuous-wave neodymium yttrium-aluminum-garnet (Nd:YAG) laser source operates at a wavelength of 1064 nm. It heats tissue around the fiber tip under ultrasound guidance.
• Radiofrequency ablation (RFA) — rapidly alternating radiofrequency electrical current creates frictional heat around probes placed inside the tissue, producing cell death by coagulation necrosis.

Because all three approaches are guided by ultrasound, doctors can direct the heat precisely at the tumor. The early studies of these techniques in thyroid disease focused on benign thyroid nodules and parathyroid adenoma (a non-cancerous parathyroid gland tumor). Success there led researchers to test the same tools on low-risk PTMC, defined as clinical stage T1N0M0 — a tumor confined to the thyroid (T1), with no lymph node spread (N0) and no distant spread (M0).

Early results showed meaningful benefits: significant shrinkage of the primary tumor, satisfactory tumor resolution, and fewer postoperative complications compared with routine surgery. The review set out to summarize these results and to compare the numbers directly across techniques.

Microwave Ablation (MWA)

Microwave ablation was widely used first for benign lesions, then expanded to solid small malignant tumors of the liver, kidney, and lung. Studies consistently showed shorter operating time, shorter recovery, shorter hospital stays, and strong therapeutic results.

The first prospective study of MWA in PTMC enrolled a small, carefully selected group of 21 patients with T1N0M0 disease. Their average tumor volume dropped dramatically — from 89.5 ± 20.1 mm³ to 8.7 ± 9.3 mm³. But there was a catch: the complete tumor disappearance rate was only 19%. That low number worried patients about how well the treatment was working. In fact, three patients in that study chose to undergo subtotal thyroidectomy and central node dissection within two months after their ablation.

Even so, the same study found few complications, no recurrence, and no metastasis after MWA. That early result opened the door to further research. As follow-up lengthened and study populations grew, the safety and effectiveness picture became clearer.

Key findings from the larger MWA studies include:

• The longest prospective follow-up reached 101 months, with an average follow-up of 37.2 months. In that series of 119 patients, the volume reduction rate (VRR — the percentage by which tumor volume shrank) reached 99.40%, complete absorption was 78.1%, complications occurred in 10.9% (13 patients), and recurrence in 0.88% (1 patient).
• Another 41-patient series had an average follow-up of 60 months — the longest reported in the literature at the time. The VRR reached 99.37%, complete absorption 97.6%, complications 4.8% (2 patients), and recurrence 0.
• A retrospective study of 185 patients with a mean follow-up of 20.7 months reported a VRR of 98.65%, complete absorption of 84.5%, complications in 8.6% (16 patients), and no recurrences.
• A retrospective study of 33 patients followed for a mean of 23.3 months reported the highest VRR of all — 99.80% — with complete absorption of 97.0%, complications in 9.10% (3 patients), and no recurrences.
• A study of 168 patients followed for a mean of 25.1 months reported complete absorption of 22.7%, complications in 4.2% (7 patients), and recurrence in 4.20% (7 patients).
• A 46-patient study with a mean 42-month follow-up reported a VRR of 81.33%, complete absorption of 15.2%, complications in 4.3% (2 patients), and no recurrences.

The most common complications tied to MWA were burning sensation, hoarseness, and hemorrhage (bleeding). Across trials, microwave power output ranged from 20 W to 40 W. Higher power and longer procedure times raised the risk of transient thermal damage to surrounding tissue.

To make sure the tumor is fully destroyed and to prevent regrowth at the edges, doctors typically ablate 5 mm beyond the visible lesion. That extra margin helps, but it can also affect nearby nerves and blood vessels — which explains some of the hoarseness and burning complaints.

The review authors note that most patients in these studies came from Asia, especially China, and most studies were retrospective or prospective observational designs. That means there is still a shortage of high-level evidence from large, multi-ethnic randomized controlled trials (RCTs) — studies in which patients are randomly assigned to different treatments.

Laser Ablation (LA)

Laser ablation works through a thin optical fiber that delivers laser energy directly into the tumor. Because the energy is focused, LA has a lower chance of damaging surrounding tissue than some other methods. It has been used to treat early-stage cancers including small hepatocellular carcinoma (liver cancer), small renal cell carcinoma (kidney cancer), and even low-risk basal cell carcinoma (a common skin cancer).

About a decade before this review, researchers led by Papini introduced LA for a solitary PTMC and reported satisfactory results. Since then, many studies — especially from China — have reached similar conclusions about its feasibility and safety.

Temperature control is the critical variable. Two failure modes exist:

• If the temperature around the fiber tip stays consistently high — especially above 110 °C — tissue can become carbonized (charred). That delays wound healing in the short term.
• If the temperature does not rise high enough, the moderate heating may fail to destroy all tumor cells, leaving residual tumor tissue that can grow back. This risk was demonstrated in laboratory experiments on liver cancer cells, operating through the PI3K/mTOR/AKT signaling pathway (a chain of molecular signals that controls cell growth and survival).

The largest comparison to date pitted LA directly against MWA in PTMC patients. Most between-group differences were not statistically significant, but two stood out:

• MWA achieved a higher volume reduction rate than LA: 99.8% vs 96.8%.
• LA had a lower complication rate than MWA: 2.9% vs 9.1%.

The explanation is straightforward. The output power of the LA device in that study was only 3 W — far less than what MWA requires. Less heat was generated, so fewer surrounding tissues were injured, but the tumor shrank less completely.

Individual LA studies reported the following results:

• 64 patients, mean follow-up 25.7 months: VRR 100.00%, complete absorption 96.9%, recurrence 1.56% (1 patient).
• 36 patients, mean follow-up 49.2 months: VRR 98.38%, complete absorption 100.0%, complications 2.80% (1 patient), recurrence 5.60% (2 patients).
• 34 patients, mean follow-up 22.8 months: VRR 96.80%, complete absorption 79.4%, complications 2.90% (1 patient), no recurrences.
• 37 patients, mean follow-up 16.5 months: complete absorption 32.4%, complications 2.70% (1 patient), recurrence 2.70% (1 patient).
• 30 patients, mean follow-up 13.2 months: complete absorption 96.7%, complications 3.30% (1 patient), no recurrences.

The review authors flag two important weaknesses in the LA evidence base. First, there is not enough clinical evidence to guarantee complete tumor destruction. Second, very few studies compare LA head-to-head against MWA, RFA, surgery, or active surveillance. Most LA studies were retrospective, with short follow-up periods ranging from roughly 18 to 52 months. Even so, the authors conclude that LA remains a promising alternative for low-risk PTMC patients who cannot undergo surgery or who decline it for personal reasons.

Radiofrequency Ablation (RFA)

Radiofrequency ablation was first developed to treat supraventricular tachycardias (abnormally fast heart rhythms). Its ability to deliver high temperatures and release energy instantly made it useful for solid tumors too. These solid tumors include tumors in the liver, kidney, and bone. These solid tumors also include soft-tissue tumors of the breast, head, and neck.

Under strict patient selection criteria, two retrospective studies from South Korea and one prospective study from China produced consistent, encouraging results. RFA was safe and effective as a treatment option for PTMC.

Researchers led by Zhang have been evaluating RFA for PTMC and PTC for years. They retrospectively analyzed clinicopathological data from over 500 PTMC patients at a single center between January 2013 and December 2017 who chose RFA treatment. Complication and recurrence rates in this group were generally acceptable, each ranging from 0% to 4.5%.

Larger RFA studies reported the following:

• 414 patients, mean follow-up 42.2 months: VRR 98.81%, complete absorption 88.4%, complications 3.86% (16 patients), recurrence 3.62% (15 patients). In this study, 15 patients developed local tumor progression after RFA: 4 patients (0.97%) developed lymph node metastasis (LNM — cancer spread to lymph nodes) and 10 patients (2.42%) developed recurrent PTMC.
• 198 patients, mean follow-up 25.9 months: VRR 99.80%, complete absorption 45.6%, complications 4.50% (9 patients), recurrence 0.51% (1 patient).
• 133 patients: VRR 100.00%, complete absorption 91.4%, complications 3.00% (4 patients), no recurrences.
• 92 patients, mean follow-up 7.8 months: VRR 96.00%, complete absorption 10.2%, complications 4.30% (4 patients), no recurrences.
• 37 patients, mean follow-up 6.0 months: VRR 99.34%, complete absorption 97.4%, no complications, no recurrences.
• 6 patients (PTMC and PTC), mean follow-up 48.5 months: VRR 98.50%, complete absorption 66.7%, no complications, no recurrences.
• 94 patients, mean follow-up 64.2 months: no complications recorded, recurrence 1.06% (1 patient).

One especially reassuring result came from a follow-up study at the same institution as the 414-patient trial. Ninety-four patients were successfully tracked for at least 5 years — the longest follow-up period identified in the review. Among them, only one developed a new lesion, and there were no other complications or lymph node metastases.

Not all results were equally encouraging. Researchers led by Xiao examined RFA in 66 patients with PTC staged T1bN0M0 (slightly larger tumors, 10–20 mm). The mean VRR reached 99.11% at 30 months, but 2 patients (3%) had malignant cells found at the edge of the ablation site, and 1 patient (1.5%) developed lymph node metastasis during follow-up.

Because of these findings, the review authors urge caution. They specifically warn against routine clinical use of RFA for early-stage T1aN0M0 PTC (tumors 10 mm or smaller) because of the risk of occult metastases — hidden cancer deposits that imaging cannot detect. Still, they conclude that RFA may be a promising option for patients who cannot tolerate surgery or who choose to decline it.

How Thermal Ablation Compares With Surgery

Surgery remains the first-line treatment for papillary thyroid carcinoma and serves as the benchmark against which all new techniques are judged. Several studies have compared the two approaches directly.

In benign thyroid tumors, thermal ablation already showed itself to be a strong alternative — with faster recovery, fewer complications, higher postoperative quality of life, and shorter hospital stays than thyroidectomy. The question was whether the same held true for cancer.

In one retrospective study of 92 PTMC patients treated with either MWA or surgery, no patient in either group experienced recurrence or lymph node metastasis over a 42-month follow-up. The cost difference was striking: the average MWA cost was 9,996.5 ± 586.47 RMB (Chinese yuan) versus 15,342.36 ± 2,226.39 RMB for surgery (p<0.001 — a difference highly unlikely to be due to chance).

Surgery carries its own risks. Removing the thyroid increases the chance of injuring the recurrent laryngeal nerves (nerves that control the voice box) or the parathyroid glands (four small glands that regulate calcium). Damage to these structures can cause hoarseness and hypocalcemia (abnormally low blood calcium), which produces symptoms such as tingling, muscle cramps, and fatigue.

When researchers expanded the comparison to 311 patients, the results held up:

• Recurrence rate and 5-year disease-free survival showed no statistically significant difference between MWA and surgery: 4.2% vs 4.2%.
• Complication rates were much lower with MWA: 4.2% vs 11.9% (p<0.001).
• Operative time, blood loss, length of hospital stay, and hospital cost were all significantly reduced with thermal ablation.

The table of comparative studies tells the story in numbers:

• MWA vs surgery (92 patients): procedure time 10.19 vs 75.80 minutes; hospital stay 1.30 vs 7.47 days; blood loss 1.54 vs 33.10 mL; complications 4.30% (2 patients) vs 43.50% (20 patients); recurrence 0 vs 0.
• MWA vs surgery (prospective): procedure time 25.02 vs 78.80 minutes; hospital stay 1.77 vs 4.18 days; blood loss 10.32 vs 33.12 mL; complications 4.90% (2 patients) vs 15.20% (7 patients).
• MWA vs surgery (311 patients): complications 4.20% (7 patients) vs 11.90% (17 patients); recurrence 4.2% (7 patients) vs 4.2% (6 patients).
• RFA vs surgery: procedure time 7.99 vs 62.90 minutes; cost 1,832.00 vs 2,355.00 US dollars; hospital stay 0.00 vs 9.35 days; blood loss 26.10 vs 31.60 mL; complications 0 vs 3.75% (3 patients); recurrence 1.1% (1 patient) vs 2.5% (2 patients).
• LA vs surgery: procedure time 25.90 vs 74.20 minutes; hospital stay 0.15 vs 2.58 days; complications 2.80% (1 patient) vs 6.70% (3 patients); recurrence 5.6% (3 patients) vs 6.7% (2 patients).
• MWA vs LA (head-to-head): procedure time 24.00 vs 26.90 minutes; hospital stay 0.14 vs 0.15 days; complications 9.10% (3 patients) vs 2.90% (1 patient); recurrence 0 vs 0.

Cosmetic and quality-of-life outcomes also favor ablation. Compared with the surgery group, PTMC patients who underwent RFA scored lower on the "problems with scarring" and "less interest in sex" sections of the THYCA-QOL (a validated thyroid-cancer-specific quality-of-life questionnaire). Thermal ablation leaves almost invisible scars on the neck rather than a surgical incision.

The sexual-function finding may connect to thyroid biology. The review notes that thyroid hormone levels can influence reproductive hormone levels as well as sexual and reproductive function.

Despite these advantages, the authors stress that randomized controlled studies with large patient numbers and longer follow-up are still required before these conclusions can be considered final.

Complications and Side Effects

Complications after thermal ablation are significantly fewer than after thyroid lobectomy or total thyroidectomy. Even so, a small proportion of patients develop symptoms related to thermal damage.

The most common problems reported across studies are:

• Transient hoarseness — temporary voice changes
• Burning sensation in the treated area
• Hemorrhage (bleeding)
• Choking and coughing
• Local infection
• Skin burning
• Hypothyroidism (underactive thyroid)
• Hypoparathyroidism (underactive parathyroid glands, leading to low calcium)
• Hematoma (a collection of blood outside blood vessels)

The reassuring news: the majority of these symptoms resolve on their own within a short time.

The review identifies two reasons why thermal damage to surrounding structures can occur. First, safety depends heavily on where the tumor sits. If the lesion lies close to the trachea (windpipe), heat can spread to sensitive nearby tissue. Second, the deliberate 5 mm safety margin around the tumor — which helps ensure complete destruction and prevents recurrence at the edges — can inadvertently affect nearby nerves and blood vessels.

Comparing complication rates across treatments shows a clear pattern. In comparative studies, ablation consistently produced fewer complications than surgery: 4.30% vs 43.50%, 4.90% vs 15.20%, 2.80% vs 6.70%, and 4.20% vs 11.90% in the respective studies.

How This Review Was Conducted

This is a narrative review, not a new clinical trial. The authors searched the PubMed database — a major index of biomedical research — for the most relevant published literature. Their search used keywords including:

• "thermal ablation"
• "papillary thyroid microcarcinoma"
• "microwave ablation"
• "radiofrequency ablation"
• "laser ablation"

They comprehensively reviewed the articles found and analyzed the follow-up outcomes of the patients described in them. They also quantitatively compared specific assessment indicators after ablation — such as volume reduction rate, complete absorption rate, complication rate, and recurrence rate — to provide a more direct comparison across techniques.

Follow-up in the reviewed studies ranged from 6 to 64.2 months. Recurrence was defined as lymph node metastasis or a new malignant lesion. Complications were defined as hoarseness, choking, coughing, local infection, skin burning, hypothyroidism, hypoparathyroidism, hemorrhage, and hematoma.

Limitations of the Evidence

The authors are direct about the weaknesses in the current evidence base. Several limitations stand out.

1. Study design. The majority of clinical trials evaluating thermal ablation were retrospective (looking backward at existing records), lacked a control group, and lacked randomization. Only a few comparative studies have directly compared thermal ablation with surgery for PTMC.
2. Population bias. Most observational patients came from Asia, especially China. Results may not apply equally to other ethnic groups or regions.
3. Missing high-level evidence. There is a lack of large, population-based, multi-ethnic randomized controlled trials to definitively evaluate efficacy and safety.
4. Short follow-up for some techniques. Although the longest follow-up reached 101 months (about 8.4 years), laser ablation evidence comes mostly from studies with short follow-up, roughly 18 to 52 months.
5. Risk of hidden disease. Occult metastases — microscopic cancer spread not visible on imaging — remain a concern, particularly for RFA in T1aN0M0 disease.

Active surveillance itself carries a psychological burden for some patients, which complicates comparisons. Because some patients are unwilling to live with an untreated tumor, comparing ablation outcomes against patients who chose surveillance is difficult.

What This Means for Patients

If you have been diagnosed with papillary thyroid microcarcinoma, here is what this review suggests you should know and discuss with your care team.

1. Ask about all your options. Three broad paths exist: surgery (lobectomy with or without lymph node dissection), active surveillance, and thermal ablation. Each has different trade-offs in recovery time, scarring, cost, and risk.
2. Understand what the numbers mean. Volume reduction rates of 96% to nearly 100% sound dramatic, and they are. But shrinkage is not the same as complete disappearance. Complete absorption rates varied widely across studies — from about 10% to 100%, depending on the technique and how long patients were followed.
3. Recurrence risk appears comparable to surgery in the studies reviewed. In the largest comparison, recurrence was 4.2% with microwave ablation versus 4.2% with surgery. That is 1 in 24 patients in each group. But these comparisons came from observational studies, not randomized trials.
4. Expect fewer complications and a faster recovery with ablation. Hospital stays were measured in fractions of a day to about 2 days with ablation versus roughly 2.6 to 9.4 days with surgery. Blood loss and operating time were also much lower.
5. Choose an experienced center. Safety depends on tumor location and on the operator's skill. Because thermal ablation typically treats a 5 mm margin beyond the tumor, the procedure's safety profile depends heavily on where the tumor sits relative to the trachea, nerves, and blood vessels.
6. Plan for long-term follow-up. Recurrence and new lesions can appear years later. In the reviewed studies, follow-up ranged from 6 months to 64.2 months — and some recurrences appeared late.
7. Be cautious with larger tumors. In patients with T1bN0M0 disease (tumors 10–20 mm), 3% had malignant cells at the ablation edge and 1.5% developed lymph node metastasis. For these patients, surgery may remain the safer choice.

The review's bottom line: thermal ablation offers the same satisfactory therapeutic effects as surgery but with minimal postoperative trauma, which can significantly improve quality of life. However, the authors emphasize that larger-sample, multicenter, prospective randomized controlled trials are urgently needed to confirm how well thermal ablation truly works for PTMC.

Frequently Asked Questions

What is thermal ablation for thyroid cancer?

Thermal ablation uses extreme heat to destroy thyroid tumor cells without surgery. Three techniques are used for papillary thyroid microcarcinoma: microwave ablation, laser ablation, and radiofrequency ablation. All are guided by ultrasound so doctors can direct heat precisely at the tumor. The dead tissue is gradually reabsorbed by the body. It is an option for low-risk tumors 10 mm or smaller.

Am I a candidate for thermal ablation instead of surgery?

Thermal ablation has been studied mainly in low-risk papillary thyroid microcarcinoma, meaning a tumor 10 mm or smaller confined to the thyroid with no lymph node or distant spread. It may suit patients who cannot undergo surgery or who decline it. For tumors 10–20 mm, one study found malignant cells at the ablation edge in 3% of patients, so surgery may remain safer.

How does thermal ablation compare with surgery for recovery and complications?

In the reviewed studies, thermal ablation produced far fewer complications than surgery, with rates like 4.2% versus 11.9% in a 311-patient comparison. Hospital stays were shorter, operating times and blood loss were lower, and costs were reduced. Recurrence rates were similar: 4.2% with microwave ablation versus 4.2% with surgery in that same comparison. These were observational studies, not randomized trials.

What does a 99% volume reduction rate mean?

Volume reduction rate is the percentage by which tumor volume shrank after treatment. Rates of 96% to nearly 100% were reported across studies. But shrinkage is not the same as complete disappearance. Complete absorption rates varied widely, from about 10% to 100%, depending on the technique and how long patients were followed. Ask your care team what these numbers mean for your specific tumor.

What side effects can happen after thermal ablation?

Reported complications include transient hoarseness, burning sensation, hemorrhage, choking, coughing, local infection, skin burning, hypothyroidism, hypoparathyroidism, and hematoma. Most resolve on their own within a short time. Safety depends on tumor location, because heat can spread to nearby structures like the trachea, and the deliberate 5 mm safety margin can affect nearby nerves and blood vessels.

Will the cancer come back after thermal ablation?

In the reviewed studies, recurrence after thermal ablation appeared comparable to surgery. In the largest comparison, recurrence was 4.2% with microwave ablation versus 4.2% with surgery, or 1 in 24 patients in each group. However, these were observational studies, not randomized trials. Recurrence and new lesions can appear years later, so long-term follow-up is important.

Why do doctors still recommend surgery for some small thyroid cancers?

Surgery remains the first-line treatment for papillary thyroid carcinoma and the benchmark against which new techniques are judged. It carries risks such as injury to nerves controlling the voice box or parathyroid glands, causing hoarseness or low calcium. For larger tumors (10–20 mm), one study found malignant cells at the ablation edge in 3% of patients and lymph node metastasis in 1.5%, so surgery may be safer.

I was just diagnosed with papillary thyroid microcarcinoma — when should I get a second opinion before choosing surgery or thermal ablation?

A second opinion is worth considering when the choice between surgery, active surveillance, and thermal ablation is unclear. Recurrence was 4.2% with microwave ablation versus 4.2% with surgery in the largest comparison, but those results came from observational studies, not randomized trials. Ablation also depends heavily on tumor location and operator skill, and for tumors 10–20 mm, 3% had malignant cells at the ablation edge. An independent review of your ultrasound, pathology, and tumor location can clarify which path fits. Diagnostic Detectives Network provides independent expert second opinions.

Source Information

Original article title: Methods description Thermal Ablation for Papillary Thyroid Microcarcinoma- How Far We Have Come

Publication: Cancer Management and Research, 2020; volume 12, pages 13369–13379. Published by Dove Press. DOI: 10.2147/CMAR.S287473.

Article type: Review article.

Note: This patient-friendly article is based on peer-reviewed research. It summarizes and translates a published scientific review. Individual treatment decisions should always be made in consultation with a qualified medical team who can evaluate your specific tumor characteristics, location, and overall health.